parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.08 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in renal collecting duct intercalated cells	0.75
chemistry Open Targets	hard to drug	0.40
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 182	0.85
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 3416

receipt 3424: CA8 in dopamine neurons, braak

power: full sample +0.02 (p 0.942, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.787, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.08 (p 0.748, n 18). could be the mix.
skeptic: leave-one-out range -0.14 to +0.12, sign flips 5; without severely affected donors +0.02 (p 0.942, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CA8 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3423: CA8 in oligodendrocytes, braak

power: full sample -0.16 (p 0.515, n 18), 95% CI -0.59 to +0.33. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.21 (p 0.413, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.13 (p 0.597, n 18). could be the mix.
skeptic: leave-one-out range -0.31 to -0.06, sign flips 0; without severely affected donors -0.16 (p 0.515, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CA8 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts